Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,690 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Nurix Therapeutics Stock Up 1.8 %

Shares of Nurix Therapeutics stock opened at $20.01 on Friday. The company has a 50-day moving average of $20.14 and a two-hundred day moving average of $22.40. Nurix Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NRIX. Squarepoint Ops LLC acquired a new stake in Nurix Therapeutics in the 2nd quarter valued at about $601,000. AQR Capital Management LLC lifted its holdings in shares of Nurix Therapeutics by 76.8% in the second quarter. AQR Capital Management LLC now owns 21,296 shares of the company’s stock valued at $444,000 after purchasing an additional 9,254 shares in the last quarter. Millennium Management LLC grew its position in shares of Nurix Therapeutics by 60.2% in the second quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock valued at $12,514,000 after purchasing an additional 225,374 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Nurix Therapeutics by 25.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company’s stock worth $479,000 after purchasing an additional 4,583 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in shares of Nurix Therapeutics during the 2nd quarter worth approximately $578,000.

Analysts Set New Price Targets

NRIX has been the topic of a number of recent research reports. Stephens restated an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. BMO Capital Markets started coverage on Nurix Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $35.00 price objective for the company. Stifel Nicolaus increased their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price on the stock. Finally, Needham & Company LLC decreased their price target on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $30.71.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.